# KLOW Peptide Research: The Component Literature, Arm by Arm > KLOW peptide research across four arms — KPV inflammation studies, GHK-Cu matrix and skin data, BPC-157 tissue-repair findings, TB-500 wound-closure evidence. Cited and attributed to each constituent. KLOW peptide research is four separate bodies of evidence. No single study has tested the blend. Each finding below carries the seal of the component it belongs to. ## In plain words KLOW peptide is made of four compounds, each with its own separate research record. This page walks those records one arm at a time. KPV quiets inflammation at the cell level. GHK-Cu — the dominant ingredient — remodels the extracellular matrix (the protein scaffold surrounding cells) and shifts gene expression toward repair. BPC-157 drives the formation of new blood vessels and repairs tendons. TB-500 (a fragment of a protein called thymosin beta-4) helps cells move to close a wound. None of the four is FDA-approved for human use. The blend itself has never been tested together in any controlled study — every finding below comes from single-compound research, in specific species, at specific doses, by specific routes. Where the evidence is in rodents, that is stated. Where human data exists, that is stated too. ## GHK-Cu: the skin-matrix current GHK-Cu (glycyl-l-histidyl-l-lysine copper complex, Copper Tripeptide-1, CAS 89030-95-5, MW 402.92 Da) is the mass-dominant component of the canonical vial at 50 of 80 mg (~62.5% by mass). It is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973; endogenous plasma levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. The foundational collagen-synthesis finding: in human fibroblast cultures, GHK-Cu stimulated collagen synthesis in a dose-dependent manner. Stimulation began between 10⁻¹² and 10⁻¹¹ M, maximized at 10⁻⁹ M, and was independent of any change in cell number — a specific metabolic effect, not just growth [8]. This 1988 Maquart et al. finding established the core mechanistic rationale for GHK-Cu as a matrix-regenerative agent. Beyond collagen, GHK-Cu stimulates synthesis of dermatan sulfate, chondroitin sulfate and the proteoglycan decorin, and increases production of VEGF (a vascular growth factor), FGF-2, NGF and neurotrophins 3 and 4 and erythropoietin, while suppressing TGF-beta-1, TNF-alpha and protein glycation [9]. At the transcriptome level, a 2018 analysis found that GHK modulates expression of approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold (note: the often-quoted '~4,000 genes' figure is an extrapolation; the ≥50% threshold table reports on the order of 2,100 genes). Expression shifts are toward tissue-repair, protein-quality-control, DNA-fidelity and antioxidant programs — the ubiquitin-proteasome system (41 genes up, 1 down) and DNA-repair gene sets among the strongest [5]. In human skin, copper applied as the GHK-Cu tripeptide penetrated dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h. Over 48 hours, 136.2 ± 17.5 μg/cm² permeated and 97 ± 6.6 μg/cm² was retained as a dermal depot — quantifying the transdermal copper delivery and depot formation that underlies topical formulation strategy [10]. Hair growth: in a 6-month placebo-controlled trial of 45 men with androgenetic alopecia (Norwood-Hamilton II-V), a topical complex of 5-aminolevulinic acid and GHK peptide (ALAVAX) increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL dose groups) versus 9.6 for placebo (p<0.05), with no adverse events in any group [11]. A 2025 study further links palmitoyl copper peptide to copper-dependent melanin synthesis in melanoma cell lines, raising questions about copper-peptide effects on hair pigmentation [15]. ## KPV: the anti-inflammatory current KPV (Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, CAS 67727-97-3, MW 342.44 Da) contributes 10 mg to the canonical vial. Its defining mechanistic feature is substrate recognition by PepT1 (SLC15A1), the di/tripeptide transporter upregulated in inflamed gut and immune tissue. PepT1 pulls KPV into intestinal epithelial cells and macrophages with a Km of approximately 160 μM — a tissue-selective uptake mechanism that concentrates the tripeptide where inflammation is highest. At the molecular level, nanomolar KPV inhibits NF-kB p65/RelA nuclear import in epithelial and immune cells and suppresses MAPK (ERK/p38) signaling, reducing TNF-alpha, IL-6, IL-1beta and IL-8 output. In Caco2-BBE and HT29-Cl.19A human intestinal epithelial cell lines and Jurkat T cells, these effects were documented at 10 nM. In C57BL/6 mice with DSS- and TNBS-induced colitis, oral KPV at 100 μM in drinking water reduced colitis severity [3]. This is the only in-vivo model for the anti-inflammatory arm of KLOW in the gut-mucosa context. A related study: the synthetic melanocortin dimer (CKPV)₂ — a larger construct built around the KPV motif — exerted anti-fungal and anti-inflammatory effects against Candida albicans vaginitis in mice by inducing macrophage M2 (the anti-inflammatory, repair-oriented polarization state) polarization [13]. This extends the picture of the KPV motif's dual anti-inflammatory and immune-modulatory potential across mucosal compartments. ## BPC-157: the angiogenic current BPC-157 (Body Protection Compound 157 / pentadecapeptide BPC 157, CAS 137525-51-0, MW 1419.53 Da, sequence GEPPPGKPADDAGLV) contributes 10 mg to the canonical vial. It is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein identified in human gastric juice, originally developed as PL 14736 for inflammatory bowel disease. Tissue-repair cornerstone: BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, in groups treated with 10 μg, 10 ng, or 10 pg per rat by intraperitoneal injection once daily. The same study showed stimulation of tendocyte outgrowth in vitro [2]. This 2003 Staresinic et al. finding is among the most-cited in the BPC-157 musculoskeletal literature. The primary known mechanism is activation of the VEGFR2 (vascular endothelial growth factor receptor 2)/PI3K/Akt/eNOS angiogenic axis — the pathway cells use to build new blood vessels from existing ones. BPC-157 also upregulates the growth-hormone receptor in tendon fibroblasts and modulates the nitric-oxide system in a manner partly resistant to L-NAME (a nitric oxide synthase inhibitor), suggesting a NO-related route distinct from classical NOS. Human data are limited. A 2025 first-in-human IV safety pilot administered intravenous BPC-157 up to 20 mg (10 mg day 1, 20 mg day 2 in 250 cc saline, 1-hour infusion) in two healthy adults — a 58-year-old male and a 68-year-old female. No adverse events were observed; no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers were recorded [6]. This is a tiny n; it is not an efficacy trial. A 2026 Sports Medicine systematic review covering approved and unapproved peptide therapies for musculoskeletal conditions — listing TB-500/thymosin beta-4 and BPC-157 explicitly — concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [7]. ## TB-500: the cell-migration current TB-500 (Ac-LKKTETQ, MW 889.02 Da) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). This distinction matters: most foundational efficacy data in the literature are for the full-length native Tbeta4, not the short TB-500 fragment. The fragment sequesters G-actin (globular monomeric actin, the raw material cells use to build a new leading edge and migrate) — the step mechanistically linked to cell migration and re-epithelialization (the process of new epithelial cells spreading to cover a wound). Full-length Tbeta4 additionally activates integrin-linked kinase (ILK) and mobilizes epicardial progenitor cells — activities established for the native protein, not demonstrated for the fragment. Wound-healing cornerstone: in a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction (≥11% by day 7) and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte migration 2-3-fold in vitro [1]. This 1999 Malinda et al. study used the native protein, not the TB-500 fragment — a distinction required by accuracy. A clinical-grade topical formulation of thymosin beta-4 (0.1% RGN-259 ophthalmic solution) promoted healing and improved corneal integrity in human corneal studies, representing one of the more advanced human-data contexts for the Tbeta4 lineage [12]. Regulatory note: TB-500/thymosin beta-4 is on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition. Because TB-500 is a component of KLOW, the blend implicates anti-doping rules in any athletic-research context regardless of intent [7]. --- A fog-lit reading room: four component literatures set down as four separate currents, each cited to its own study, the absent blend experiment kept openly dark.